Silver Nanoparticles and HIV
Silver Nanoparticles and HIV
- It is estimated that 5-78% of patients treated with HIV-1 are resistant to antiretroviral therapy. This gap in effectiveness created by the emergence of resistance creates a need for new anti-HIV agents to cover different stages of the viral life cycle. Silver nanoparticles have antiviral activity against HIV-1.
- It is estimated that 5-78% of patients treated with HIV-1 are resistant to antiretroviral therapy. This gap in effectiveness created by the emergence of resistance creates a need for new anti-HIV agents to cover different stages of the viral life cycle. Silver nanoparticles have antiviral activity against HIV-1.